Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Find Stocks Tailored to Your Trading Interests

benzingaproreview-1-1280x720

acf/call-to-action

<a href="https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh">Claim Exclusive Offers</a>

Compare Investing Brokers (USE THIS ONE)

acf/widget-container

acf/compare-products

Plus500 Yield

IBKR Stocks

public.com

Moomoo

Webull

<a href="https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh">Claim Exclusive Offers</a>

Compare Crypto Brokers Homepage

Plus500 Crypto

Kraken

Webull Crypto

FxGlory

eToro

Uphold Crypto

Compare Brokers Table – Benzinga.com

CG Oncology

Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends.

Charlie Yang's

analyst ratings image

9 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

Analysts have recently evaluated CG Oncology and provided 12-month price targets. The average target is $68.33, accompanied by a high estimate of $75.00 and a low estimate of $50.00. This current average has decreased by 1.92% from the previous average price target of $69.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1719586894_0.png" alt="price target chart" />

<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive CG Oncology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charlie Yang</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Andres Maldonado</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Corinne Johnson</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Corinne Johnson</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Andres Maldonado</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andres Maldonado</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andres Maldonado</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>-</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CG Oncology. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CG Oncology compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CG Oncology's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CGON/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CG Oncology analyst ratings.</a>
<h2>Discovering CG Oncology: A Closer Look</h2>
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
<h3>Unraveling the Financial Story of CG Oncology</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, CG Oncology showcased positive performance, achieving a revenue growth rate of 172.68% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: CG Oncology's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -3200.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CG Oncology's ROE excels beyond industry benchmarks, reaching -7.6%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): CG Oncology's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.35%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.0, CG Oncology adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CGON

A Closer Look at 9 Analyst Recommendations For CG Oncology

BofA Securities&nbsp;has downgraded&nbsp;Vir Biotechnology Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) to Neutral from Buy with a price target of $14,&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/quote/VIR/analyst-ratings" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">down from $23</a>.

Analysts&nbsp;Geoff Meacham, Charlie Yang, Susan Chor, Hao Shen, and Alexandria Hammond note that VIR&#39;s stock performance YTD has been lackluster, with a decline of 54%, compared to the NBI index&#39;s marginal decrease of 4% primarily attributed to disappointing&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/07/33303864/why-vir-biotechnology-stock-is-plunging-today" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">influenza A and HBV data</a>.&nbsp;

However, the analysts maintain a positive outlook on Vir&#39;s antibody platform and recognize its long-term potential.

In terms of its pipeline, Vir encountered some challenges in 2023. However, it&#39;s worth noting that Vir is actively developing a next-generation flu antibody.&nbsp;

Additionally, several upcoming Hepatitis B virus trial readouts are featuring various combination regimens over the next 18 months. However, these are unlikely to change investor sentiment materially.

BofA anticipates results for the Vir-2218 + Vir-3434 + PEG-INF (triple combo) with 24 weeks of treatment data in HBV (March Part B) in Q4 2023.

Insights from key opinion leaders suggest that the triple combo must demonstrate a substantial functional cure rate to achieve commercial success, ideally exceeding 40-50% clearance. However, functional cure data won&#39;t be available until Q2 of 2024.

Also, initial data from the SOLSTICE trial of VIR-2218 + VIR-3434 in the Hepatitis D virus is expected. The analysts will monitor this combination&#39;s efficacy, aiming for results comparable to&nbsp;Gilead Sciences Inc&#39;s&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/gild#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">GILD</a>) bulevirtide, which achieved a response rate of 45-48%.&nbsp;

Price Action:&nbsp;VIR shares are down 5.62% at $10.91 on the last check Friday.

Analyst Color

Biotech

News

Downgrades

Health Care

Price Target

Small Cap

Movers

Trading Ideas

General

GILD

BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14, 

Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades

Earnings

CSIQ

Canadian Solar Q1&#39;16 Earnings Conference Call: Full Transcript

Analyst Ratings Newsletter

Don't Miss Your Daily Analyst Rating Email!!!

acf/newsletter-subscription-box

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Charlie Yang's Stock Ratings

B of A Securities Analyst

Overall Average Return

Smart Score

Overall Average Return Percentile

Number of Ratings

Recent Analyst Stock Rating News